Clinical trials: Genomic Instability
Microsatellite Instability, Colorectal Cancer Stage IV
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
This pilot trial studies how well serial liquid biopsies work in detecting microsatellite instability in participants with stage IV colorectal cancer.
- Trial name
- NCT03594448
- Testing
- Specimen Collection, Serial Liquid Biopsy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Colorectal Medullary Carcinoma
Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study
Medullary carcinoma (MC) is a rare tumor with solid growth pattern without glandular differentiation and constitute less than 1% of colorectal cancer.
- Trial name
- NCT03774862
- Volunteers
- 13 people
- Sponsor
- V.K.V. American Hospital, Istanbul
Localized Oesogastric Adenocarcimona, MSI and or dMMR
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
This is a non-randomized study, open label phase II study. The purpose of this study is to evaluate the complete pathologic response rate (cPRR) with neoadjuvant nivolumab and ipilimumab combination in patients with MSI and/or…
- Trial name
- NEONIPIGA (NCT04006262)
- Testing
- Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection
- Where
- 15 sites in France
- Volunteers
- 32 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Cytogenetic Abnormality, Radiation Exposure
Genomic Instability in Vascular Surgeons
The past two decades have witnessed the development and growth of the endovascular techniques, however, this new technology is not exempt from risks, since its use requires an ionizing radiation exposure to both patients and…
- Trial name
- IRADIENT (NCT04363190)
- Testing
- Cytogenetic analysis
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma
Chromosomal Instability in Ovarian Cancer
Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure.
- Conditions
- Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Chromosomal Instability, Somatic Copy Number Distortion
- Trial name
- NCT05310357
- Testing
- Testing for chromosomal instability (CIN)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Lei Li
Bladder Cancer
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor…
- Trial name
- NCT06153849
- Testing
- urine sample collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Colorectal Cancer
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)
- Trial name
- NCT06428487
- Testing
- Prolgolimab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability
- Trial name
- NCT02966587
- Testing
- Durvalumab, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Washington
Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer
Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch Syndrome
Lynch syndrome (LS) is an autosomal dominant hereditary condition that markedly increases the risk of colorectal cancer (CRC) and other malignancies.
- Conditions
- Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer, HNPCC, Colorectal Cancer (CRC)
- Trial name
- BioLynch (NCT07838246)
- Testing
- Study procedures
- Where
- Italy
- Volunteers
- 109 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Colorectal Cancer, Microsatellite Instability
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact
MSI (Microsatellite Instability) colorectal cancer (CRC) show improved survival, are less prone to metastasis and show poor response to chemotherapy (compared to MSS tumors).
- Trial name
- NCT03447431
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris